Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Sepimostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 2/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.48 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.48 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.47 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.47 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.47 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.47 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.47 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.47 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 1.00 |
| ▸ | C1R | P00736 | 2/20 | 1.00 |
| ▸ | F10 | P00742 | 2/20 | 1.00 |
| ▸ | KLK1 | P06870 | 2/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 1/20 | 1.00 |
| ▸ | F12 | P00748 | 4/20 | 0.91 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.91 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepimostat SCHEMBL15536391 | 1.00 | PRSS1 (1.00) | PRSS1F2C1RF10KLK1 | |
| Sepimostat SCHEMBL29406588 | 1.00 | PRSS1 (1.00) | PRSS1F2C1RF10KLK1 | |
| Sepimostat SCHEMBL872319 | 0.95 | F12 (1.00) | PRSS1F2C1RF10KLK1 | |
| Sepimostat SCHEMBL9825206 | 0.94 | F12 (0.98) | PRSS1F2C1RF10KLK1 | |
| SCHEMBL7598149 | 0.84 | PRSS1 (0.73) | PRSS1F2C1RF10KLK1 | |
| SCHEMBL10035205 | 0.83 | PRSS1 (0.74) | PRSS1F2C1RF10KLK1 | |
| SCHEMBL7563393 | 0.82 | PRSS1 (0.70) | PRSS1F2C1RF10KLK1 | |
| SCHEMBL7561463 | 0.82 | PRSS1 (0.69) | PRSS1F2C1RF10KLK1 | |
| Hydrochloric Acid SCHEMBL7563216 | 0.79 | PRSS1 (0.68) | PRSS1F2C1RF10KLK1 | |
| Nafamostat SCHEMBL564665 | 0.78 | FTO (0.70) | PRSS1F2C1RF10KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008142397-A1 | SERINE PROTEASE INHIBITORS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | SERENTIS LIMITED (GB) | 2008-11-27 | — | — | WO | claimed |
| US-4777182-A | ENZYME, HORMONE, COMPLEMENT INHIBITORS | TORII & CO., LTD. (JP) | 1988-10-11 | — | — | US | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | ASCENDIS PHARMA A/S (DK) | 2021-09-14 | — | — | US | disclosed |
| EP-3782649-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | Ascendis Pharma A/S (DK) | 2021-02-24 | — | — | EP | disclosed |
| EP-1246824-A1 | CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Aventis Pharma S.A. (FR) | 2002-10-09 | — | — | EP | disclosed |
| EP-0802179-B1 | SUBSTITUTED AMIDINONAPHTHYL ESTER DERIVATIVES | TORII PHARMACEUTICAL CO LTD (JP) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001047930-A1 | CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-07-05 | — | — | WO | disclosed |
| US-5885990-A | FIBRINOLYSIS PROMOTING ACTION; THROMBOLYSIS ACTION | TORII PHARMACEUTICAL CO., LTD. (JP) | 1999-03-23 | — | — | US | disclosed |
| EP-0802179-A1 | SUBSTITUTED AMIDINONAPHTHYL ESTER DERIVATIVES | TORII PHARMACEUTICAL CO., LTD. (JP) | 1997-10-22 | — | — | EP | disclosed |
| EP-0190356-B1 | NOVEL AMIDINE COMPOUNDS | TORII & CO., LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4820730-A | ANTI-TRYPSIN, ANTI-PLASMIN, ANTI-THROMBIN, ANTI-KALLIKREIN ACTIVITY | TORII & CO., LTD. (JP) | 1989-04-11 | — | — | US | disclosed |
| US-4777182-A | ENZYME, HORMONE, COMPLEMENT INHIBITORS | TORII & CO., LTD. (JP) | 1988-10-11 | — | — | US | disclosed |
| EP-0190356-A1 | NOVEL AMIDINE COMPOUNDS | TORII & CO., LTD. (JP) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | F2 1990/4885ADRA2B 3726/4885ADRA2C 4224/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | F2 2824/4885ADRA2B 149/4885ADRA2C 884/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | F2 1990/4885ADRA2B 3726/4885ADRA2C 4224/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | F2 2824/4885ADRA2B 149/4885ADRA2C 884/4885 |
| US-11116849-B2 | Hydrogel-linked prodrugs releasing tagged drugs | PTMS, PGLS, PAM | F2 4510/4885ADRA2B 1234/4885ADRA2C 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.